SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Conditions: AML/MDS; CD33 Expressing Hematological Malignancies; FLT3 Expressing Hematological Malignancies Interventions: Biological: SENTI-202 Sponsors: Senti Biosciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials